Overview

NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens

Status:
NOT_YET_RECRUITING

Trial end date:
2026-05-01

Target enrollment:

Participant gender:

Summary

The objective of this Prospective, randomized, non inferiority phase III trial is to confirm the efficacy and saftey of dexamethasone-sparing combined with netupitant/palonostron and olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Phase:

PHASE3

Details

Lead Sponsor:

Fudan University

Treatments:

Dexamethasone
netupitant
netupitant, palosentron drug combination
Olanzapine
Palonosetron